
This marks the fourth drug, and first oral antiviral pill, approved by the FDA to treat adults with mild-to-moderate COVID-19.

This marks the fourth drug, and first oral antiviral pill, approved by the FDA to treat adults with mild-to-moderate COVID-19.

It is the second anti-TNFα biosimilar approved for use in the US.

Technicians should take advantage of opportunities to work at a higher level of practice, build their careers.

Eating regimen shows many health benefits, but the diet may not be appropriate for all patients.

The use of semaglutide for adolescents was included in recent pediatric guidelines, though there are few studies assessing the drug in this patient population.

Hispanic communities are more likely to use telehealth services, whereas non-Hispanic Black individuals continue to show telehealth inequities.

Sexual minority populations disproportionately suffer from mental health conditions as well, which could partially impact cardiovascular health, a recent study indicates.

The drug is available in 2 formulations, including a weekly injection with a lower dose than previously available as well as a monthly injection.

Pharmacy Times spoke with 2 presenters at the American Association of Pharmacy Technicians Convention 2023, which covered Wellbutrin and opioid use disorder medication.

EUA restriction for hospitalized patients was basis for lawsuit that advanced several arguments.

Devices that measure blood pressure in the upper arm would be the best choice for a more accurate and reliable reading.

Reporting vaccination data to Immunization Information Systems databases can support public health surveillance activities.

Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.

The preventive effect is believed to be a result of compounds unique to cranberries called proanthocyanidins.

The FDA’s final decision is expected by a Prescription Drug User Fee Act goal date in August 2023.

Adalimumab-adbm (Cyltezo Pen; Boehringer Ingelheim) is approved by the FDA as an interchangeable biosimilar to Humira.

Death occurs from air embolism after pneumatic line was connected to an intravenous catheter.

The diagnosis should change from an influenza infection if the patient has gradually increasing chest pain after the original diagnosis.

Anne Cassity, JD, senior vice president of Public Affairs at the National Community Pharmacists Association discusses congressional and lawmaker trends on pharmacy benefits manager reform with guests, Adam Harbison and Kaite Krell.

The risk of long COVID-19 in females in the least deprived areas was comparable to the risk of males in the most deprived areas.

A barrier in effectively treating HIV has been the latency of infected CD4+ T cells, which are often treatment-resistant and contribute to the persistence nature of the virus.

Long-term data show that early treatment with ofatumumab decreased confirmed disability worsening in nearly all study patients with relapsing multiple sclerosis.

Products include a 3-in-1 probiotic product and OTC hearing aids.

OTC nicotine replacement products can come in a transdermal patch, nicotine gum, or lozenges.

The approval marks the first and only FDA-approved treatment for dry eye disease that directly targets tear evaporation.

These appointments help identify medication-related problems and serve as a platform for additional education.

Nanoparticles could improve the solubility of drugs, aid in treatment escape from the immune system, and increase the half-life of drugs in the circulatory system against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus.

Targeted PrEP advertisements with different types of couples and sociodemographic characteristics were more eye-catching, motivating, relatable, and memorable.

Amid various obstacles, health care providers and pharmacists can initiate measures to enhance compensation for pharmacy services in managed care.

In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.